jsmc-10179

UMBILICAL VEIN INJECTION OF 800 MICROGRAM MISOPROSTOL VERSUS OXYTOCIN IN THE MANAGEMENT OF RETAINED PLACENTA

Maryam Bakir Mahmood a, Maida Y Shamdeen b and Bafrin H. Hamadmeen c

a Department of Gynecology and Obstetrics, College of Medicine, University of Sulaimani.

c Kurdistan Board Medical Studies Candidate.

Submitted: 5/7/2018; Accepted: 5/11/2018; Published 21/12/2018

DOI Link: https://doi.org/10.17656/jsmc.10179

ABSTRACT

Background

The third stage of labor is timed from the delivery of the baby to the expulsion of the placenta and membranes. This normally takes five and fifteen minutes. It may be complicated with retained placenta. Consequently, intervention should be started promptly.

Objectives

We aimed to evaluate the effectiveness of umbilical vein injection of misoprostol (800 Microgram) versus oxytocin (20 units) for the treatment of retained placenta.

Materials and Methods

This is a double-blinded randomized clinical trial, conducted at the Maternity Teaching Hospital, Sulaimani, Kurdistan Region, Iraq, from October 1, 2016 to December 31, 2017. Fifty patients whom delivered vaginally and complicated by retained placenta were randomly allocated into two groups;group1 received 800 mcg of misoprostol (four Misotac® 200 mcg, Pfizer) and, group2 received 20 IU of oxytocin (NOVARTIS) each diluted in 20 ml of normal saline were infused through umbilical vein for the two groups respectively. The outcome was measured by using time interval of placental separation and amount of blood loss.

Results

The mean ± SD age was (30.5 ± 5.8) and (27.8 ± 5) for the oxytocin and misoprostol groups respectively. There were a statistically significant relationship between the type of drug injections and a statistically very highly significant difference between the type of drug injections and time interval for the placental separation (P-value of 0.04 and P-value of <0.001 respectively). There was also a statistical significant difference in the mean vaginal blood loss between the two groups (169.3 ± 88.1 ml, 150 ± 89.4 ml) in oxytocin and misoprostol groups respectively), (P-value = 0.03).

Conclusions

The intraumbilical vein injection of misoprostol was better than oxytocin for the reduction of time needed till placental separation and associated with less blood loss.

KEYWORDS

Intraumbilical vein injection; Retained placenta, Misoprostol, Oxytocin.

References

1. McEwan A. Labour.Third stage of labour, In: Obstetrics by Ten Teacher.19th ed. Baker PN, Kenny IC.London: Hodder& Stoughton Ltd; 2011,p.202

2.Tsu VD, Langer A, AldrichT. Postpartum haemorrhage in developing countries: is the public health community using the right tools?Int J Gynaecol Obstet. 2004 Jun; 85 suppl. 1: S42-S51.

3. Rajab SS, Alalaf SK. Umbilical vein injection of misoprostol versus normal saline for the treatment of retained placenta: intrapartum placebo-controlled trial. BMC Pregnancy Childbirth. 2014;14:37.http://www.biomedcentral.com/1471-2393/14/37.

4. Weeks AD. The Retained placenta. In: Studd J, Tan SL, Chervenak FA. Progress in Obstetrics and Gynaecology. Ed.17. Liverpool: Elsevier, 2006.

5. Ramsey PS, Savage K, Lincoln T, Owen J. Vaginal misoprostol versus concentrated oxytocin and vaginal PGE2 for second-trimester labor induction.Obstet Gynecol. 2004 Jul;104(1):138-45.

6. Simms-Stewart D, Thame M, Hemans-Keen A, Hambleton I, Serjeant GR. Retained placenta in homozygous sickle cell disease.Obstet Gynecol. 2009 Oct;114(4):825-8.

7.Royal College of Obstetrician and Gynaecology, Clamping of the Umbilical cord and Placental Transfusion ,scientific Impact paper No.14 ,February 2015.

8. Abedi P, Jahanfar S, Namvar F, Lee J. Breastfeeding or nipple stimulation for reducing postpartum haemorrhage in the third stage of labour. Cochrane Database Syst Rev. 2016;(1):CD010845.

9 .Prata N, Weidert K. Efficacy of misoprostol for the treatment of postpartum hemorrhage: current knowledge and implications for health care planning. Int J Womens Health. 2016 Jul 29; 8: 341-349. DOI: 10.2147/IJWH.S89315. eCollection 2016.

10.Institute of Obstetrician and Gynaecologists,Royal College of physicians of Ireland and the Clinical Strategy and programmes Division, Health Service Executive. Clinical practice guideline oxytocin to accelerate or induce labour.[Internet]. 2016 [cited 2018 March 24]. Available from: https://rcpi-live-cdn.s3.amazonaws.com/wp-content/uploads/2016/05/31.-Oxytocin-to-Accelerate-or-Induce-Labour.pdf.

11. Leader J, Bujnovsky M, Carlan SJ, Triana T, Richichi K. Effect of oral misoprostol after second-trimester delivery: a randomized, blinded study.Obstet Gynecol. 2002 Oct; 100(4): 689-694.

12. Maher MA, Sayyed TM, Elkhouly NI. Different routes and forms of uterotonics for treatment of retained placenta: a randomized clinical trial. J Matern Fetal Neonatal Med. 2017 Sep; 30(18): 2179-2184. DOI: 10.1080/14767058.2016.124212.

13. Harara R, Hanafy S, Zidan MS, Alberry M. Intraumbilical vein injection of three different uterotonics in the management of retained placenta.J Obstet Gynaecol Res. 2011 Sep; 37(9): 1203-1207. DOI: 10.1111/j.1447-0756.2010.01499.x.

Full Text

This work is licensed under a Creative Commons Attribution 4.0 International License.